A one-time injection of a novel gene therapy was able to save mice and a newborn calf from succumbing to maple syrup urine ...

Up to 60 new life sciences companies are set to benefit from 1.6 billion euros ($1.68 billion) that Sofinnova Partners has ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

The KidneyVault is more than a simple ice chest. It pumps a cooled, specialized solution through the organ to help preserve ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

Boston Scientific is diving into the field of renal denervation, with a $540 million deal for SoniVie and its ...

Neumora halted one trial of its depression drug navacaprant and paused a pair of late-stage studies as it tries to learn from ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...